To describe better the clinical, biological, endoscopic and pathological presentations, as well as the outcome, of primary follicular lymphoma (FL) of the gastrointestinal (GI) tract.
Introduction
Non-Hodgkin's lymphomas of the gastrointestinal (GI) tract are the most common extra nodal lymphomas. They represent between 30% to 70% of all extra nodal lymphomas and constitute a heterogeneous group of tumors with different clinical and pathological features [1, 2] . Multiple definitions of primary GI lymphoma exist; at least two of them are in use. The definition by Dawson et al. in 1966 was restricted to localized disease of stages IE and IIE, whereas that by Lewin et al. [3] required that patients exhibit GI symptoms or a predominant lesion. The stomach is predominantly involved followed by the small intestine. High-grade lymphomas are the most common histological subtype encountered in the GI tract, except in the stomach, where low grade B-cell lymphomas are dominant [1, 4, 5] . The phenotype is predominantly of B-cell type (large cell, Burkitt's), whereas T-cell lymphomas are rare and usually arise in the small intestine [1] . MALT type lymphomas are the most frequent low grade nonHodgkin's lymphomas encountered in the GI tract. They account for 40% of all primary gastric lymphomas and remain, in the majority of cases, localized for a prolonged period of time without therapy [6] . Multiple lymphomatous polyposis represents <10% of primary GI lymphomas and are characterized by poor prognosis [7] . Follicular lymphomas (FL) are the second most common type of lymphomas among adults in western countries and typically arise in lymph nodes with spleen, liver and bone marrow involvement. They are characterized by their risk of transformation into high-grade lymphoma [8] . Primary extra nodal FL without peripheral lymphadenopathy is very uncommon. They constitute <7% of primary lymphoma of the GI tract in the few GI lymphoma series that have been reported [1, 5, 9, 10] . Since diagnosis, prognosis and treatment of these lymphomas remain largely unknown, we have, retrospectively, studied the clinical, biological and endoscopic characteristics, as well as the outcome, of 25 patients with primary follicular lymphoma of the gastrointestinal tract (PFLGI).
Patients and methods

Patients
From November 1983 to February 2001, 39 patients with a diagnosis of PFLGI were retrieved from the files of several French hematology and gastrointestinal departments. The search was based on histological and immunophenotype (CD20+, CD10+, BcL2+, CD5-) diagnosis. Patients were considered eligible for the study if they met the definition for primary GI nonHodgkin's lymphoma as defined by Lewin et al. [3] .
Diagnostic and staging procedures
The clinical, biological, endoscopic and radiological data were collected directly from the referring physicians. The diagnostic work-up and staging procedures on presentation included patient history and complete physical examination, full blood cell count, serum lactate dehydrogenase, β2-microglobulin, liver enzymes, alkaline phosphatase and creatinine levels, albumin level, chest X-ray, computed tomography (CT) scan of the chest, abdomen and the pelvis, endoscopic evaluation with multiple biopsies of the upper and lower GI tract, small bowel enema whenever available and bone marrow biopsy. Patients were staged according to the criteria of the recent International Workshop [11] (Table 1 ). In cases of surgical resection, the operating sheets and the histopathological certificates were used for the staging procedures. Those with predominantly GI disease with minimal extra intestinal lesions were not excluded [3] . Lesions were classified as multifocal when more than one lesion was observed.
Histological and immunohistochemical analysis
Slides or paraffin blocks were requested from the referring pathologists. Samples collected were reviewed by three pathologists. Samples were obtained from primitive digestive FL either at initial presentation (n = 24) or at recurrence in one case (13 years after the initial small bowel resection). Seventeen cases were from biopsy samples and eight cases from surgical samples. Morphological analysis was performed on routine paraffinembedded formalin fixed tissue stained with hematoxylin-eosin. We studied the following data: localization of FL, depth of tumoral infiltration, epithelial surface damage, infiltrative pattern (follicular or follicular and diffuse), percentage of large cells (<5%, 5-15%, >15%) to classify FL into three subtypes (1, 2 or 3) according to the World Health Organization (WHO) classification [12, 13] , cytological composition of the reactive inflammatory cells and the lympho-epithelial lesions. In surgical samples, size of tumor and lymph node infiltration were also noted. Phenotypic analysis was studied by immunohistochemistry performed on paraffin-embedded or frozen sections using a three-stage indirect immunoperoxidase technique. Antibodies used were a polyclonal anti-CD3 antibody (DAKO, Glostrup, Germany), monoclonal antibodies directed against CD20, bcl2 and CNA-42 (DAKO), CD5 and CD10 (Novocastra, Newcastle, UK) and CD43 (Immunotech, Marseille, France).
Molecular analysis
For the molecular study of IgH/bcl-2 rearrangements at the MBR locus, DNA was extracted either from frozen or paraffin-embedded tissue according to standardized methods [14] . A standard one-stage PCR assay was performed with MBR and JH consensus primers as previously described [15] . The final products were then size fractionated by agarose gel electrophoresis or resophor  (eurobio, France).
Results
Patient characteristics
Of the 39 patients reported with a diagnosis of PFLGI, 14 cases were excluded due to secondary intestinal involvement (n = 3), incomplete medical records (n = 5) or stage III or IV disease with an important extra-intestinal involvement (lymph nodes or diffuse bone marrow infiltration) (n = 4). Two patients were reclassified as diffuse small B-cell lymphomas. Thus, a total of 25 cases were finally analyzed. One of these cases has already been reported [16] . There was a clear female predominance with 17 females (68%) and eight males (32%). Median age at presentation was 56 years (range 44-71). In most cases, clinical presentations were abdominal pain, change of bowel habit and/or abdominal obstruction (Table 2 ). Abdominal obstruction was usually seen when the small intestine was involved, and rectal bleedings were observed in rectal and distal colon involvement. Two patients presented with weight loss that was associated in one case with exsudative enteropathy, diarrhea and hypoalbuminaemia, and in another case with diarrhea. Presentation with iron deficiency anemia was associated, in one case, with obvious bleeding and with malabsorption in the second case. Acute abdominal pain was rare and was the presenting feature in one case with intestinal invagination. The entire intestine may be affected (Tables 3 and 4 ). The most frequent site of involvement was the small intestine, with a predilection for the ileum and ileo-cecal region, followed by the duodenum, although in some cases the entire intestine was affected (Tables 3 and 4) . Lymphomas were unifocal in around half of cases (15/25; 56%). In the duodenum and the small intestine, lesions were unifocal in 44% and 38% of cases, respectively. In contrast, the majority of non-Hodgkin's lymphomas of the colon, rectum and all gastric lymphomas (n = 3) were multifocal. A precise description of the endoscopic aspects was available for 14 patients. The macroscopic aspects were heterogeneous with ulcerations (n = 1), nodules and tumors (n = 3), infiltration with inflammatory aspect (n = 2) or invagination (n = 1). Strikingly, seven cases presented a polypoid aspect as seen in lymphomatous polyposis ( Figure 1 ). Lactate dehydrogenase levels were normal in the majority of cases (n = 21/22) and β2-microglobulin levels were normal in all tested patients (18 cases). According to the classification proposed by the International Workshop, 12 patients had stage I and 10 patients had stage II disease. Three patients with a minimal bone marrow infiltration of <5% were classified as stage IV disease (Table 1) .
Pathological, phenotypical and molecular analysis
The diagnosis of FL was carried out on samples obtained by endoscopy (n = 17) or by surgical resection (n = 8). The sites of the tumor and the pattern of lesions (unifocal or multifocal) is noted in Tables 3 and 4 . No histological variations were observed between the different sites examined. The lymphoid proliferation consisted of neoplastic follicles mostly medium in size, uniform in shape and involving the mucosa. Diffuse infiltration of the muscular layer of the mucosa and/or superficial part of the submucosa was seen in four cases. Tumoral infiltration of the surface epithelium was seen in two cases. Superficial ulceration was seen in two cases. Macroscopic examination noted a white and firm tumor mass the size of which varied from 2 to 8 cm (mean 4.6 cm) in width in two patients. Extension of the tumor was pan parietal in six cases, limited to the sub mucosa in one case or muscular in one case. Peritoneal perforation was seen in one case. Among the six cases exhibiting mesenteric lymph nodes, four had tumoral infiltration. No alteration of the adjacent mucosa was seen. There were no villous atrophy or significant increase in the intraepithelial lymphocyte number. The proliferation was CD20+, bcl2+ and CD10+, CD5-or CD43-in all cases (Table 5 ; Figure 2 ). Of the 14 patients analyzed for IgH/bcl2 gene rearrangements at the MBR locus, 11 cases were positive and four cases were negative.
Treatment and outcome
The indication for therapy was dominated by clinical symptoms. Only one patient was asymptomatic, in whom the diagnostic procedure was justified by the presence of mesenteric lymph nodes with intestinal and mesenteric thickening on an abdominal CT scan that was performed for another reason. Seven patients did not receive any treatment (NT) after diagnosis-five had unifocal tumors and two had multifocal lesions. Progression of disease was documented in four of them who then received subsequent therapy. Median time to progression was 37.5 months (range 4-87). It is noteworthy that one of these patients developed central nervous system involvement 4 months thereafter and died. Six patients were alive with stable disease at a median time of 25 months (range 8-87).
Eighteen patients received therapy at diagnosis ( Table 6 ). The initial treatment was heterogeneous and consisted of complete surgical excision (CSR) alone (n = 4), chemotherapy alone (n = 10), complete surgical resection followed by chemotherapy (n = 2) or chemotherapy plus radiotherapy (n = 2). Complete remission was obtained in 15 patients (four after CSR, seven after chemotherapy alone, two after CSR plus chemotherapy and two patients after chemotherapy plus radiotherapy). One patient had a partial response, another one failed to respond and one patient was not evaluable because of early death from concomitant adenocarcinoma of the colon. Median duration of the first CR was 31 months (range 21-120). Six patients (33%) subsequently relapsed. Four of them had multifocal disease at presentation and two unifocal lesions. Relapses occurred locally in one patient, locoregionally in two patients and outside the GI tract in three. They occurred after CSR (n = 1), CSR plus chemotherapy (n = 1), chemotherapy alone (n = 3) or chemotherapy plus radiotherapy (n = 1). All these relapses were sensitive to second-line chemotherapy. Four patients experienced second relapse and one patient a third relapse after chemotherapy. After a median followup of 42 months (range 5-203), 16 patients were alive, either in complete remission (n = 11), partial remission (n = 3), progressive disease (n = 1) or with stable disease (n = 1). One patient relapsed with a large B-cell lymphoma in the GI tract at 21 months after complete resection and subsequently died from acute lymphoblastic leukemia 56 months after diagnosis. For all patients, the median follow-up was 34 months (range 5-203). Twenty-two patients were still alive ( Figure 3 ) in complete remission (n = 11), partial remission (n = 3), stable disease (n = 6) or with progressive disease (n = 2). Three patients died from concomitant colic adenocarcinoma (n = 1), progression of the disease (n = 1) and acute lymphoblastic leukemia (n = 1) at 2, 15 and 56 months, respectively.
Discussion
Primary gastrointestinal lymphoma is a heterogeneous and relatively rare disease accounting for 11-34% of all non-Hodgkin's lymphomas, with some regional variability in the frequency and histological type [1, 10, 17, 18] . Lymphomas in this setting are usually of the B-cell phenotype and are dominated by the diffuse large-cell subtype [1] . Histological subtypes of indolent lymphomas are closely related to the site involved and are dominated by the MALT type, which is primarily localized in the stomach [1, 19] . Primary follicular lymphomas of the gastrointestinal tract are very rare and constitute <7% of all non-Hodgkin's lymphomas at this location [2, 5] . In our large group of patients, the median age is not different from that of nodal FL. In contrast to their nodal counterpart or to other primary GI lymphomas [8, 20] , and in accordance with other reports on PFLGI [21, 22] , a female predominance is observed. As with other GI malignancies, the initial clinical manifestations and, to some extent, the gross appearance of the lesions appears to be related to the site of GI involvement. Thus, obstructing masses or wall thickening was more frequent in small bowel involvement (5/5 cases), whereas polyps were predominant in the colon and rectum (5/7 cases). In accordance with a series by LeBrun et al. [22] , the small intestine was the site preferentially involved. The high frequency of small intestine involvement is probably related to the relative abundance of normal lymphoid follicles in this region. The macroscopic appearance of PFLGI are very heterogeneous and there is no correlation with their histological characteristics. Lymphomatous polyposis constitutes 2% of primary GI lymphomas and corresponds, in the majority of cases, to mantle cell lymphoma [19] . A few isolated reports have suggested that lymphomatous polyposis might be made up from a heterogeneous group of lymphomas [22] [23] [24] [25] [26] . Strikingly, in our large group of patients, 50% of PFLGI had an endoscopic aspect of multiple lymphomatous polyposis. These findings are important clinically, since mantle cell lymphoma has a poor prognosis and requires aggressive first-line high-dose therapy [27, 28] . Therefore, immunophenotyping with immunostaining for CD5, CD10, cyclin D1 and bcl2, and molecular biology studies looking for the presence of IgH/bcl2 or IgH/bcl1, are advisable in order to differentiate between a diagnosis of lymphomatous polyposis and that of FL. Since PFLGI is very rare, it is difficult to provide a definitive therapeutic approach. The prognosis seems, however, not to be different from nodal FL with an indolent course even in the absence of specific treatment. Surgery and chemotherapy should be indicated only on the basis of clinical symptoms. Furthermore, and based on our findings, first-line chemotherapy does not seem to be beneficial unless clinical symptoms are important. Indeed, 33% of patients which were treated at diagnosis with surgery and/ or chemotherapy and/or radiotherapy relapsed after a median time of 31 months, not that different from the median time to progression of the disease (37.5 months) in patients who did not receive any treatment.
In conclusion, FL of the GI tract is a predominantly female lymphoma with a predilection to the ileum. The clinical course is generally indolent and endoscopic appearance may be identical to lymphomatous polyposis, which indicates the need for immunophenotyping and even molecular biology studies for diagnosis. Therapeutic interventions are not indicated unless clinical symptoms are present or the disease is progressive.
